News AbbVie Inc. Deutsche Boerse AG

Equities

Market Closed - Deutsche Boerse AG Other stock markets 13:56:04 01/07/2024 BST			5-day change	1st Jan Change
159.5 ^EUR	+0.34%		-0.68%	+14.61%

07-01	Merus Names New Chief Medical Officer	MT
07-01	AbbVie: new CEO takes up post	CF

Merus Names New Chief Medical Officer	07-01	MT
AbbVie: new CEO takes up post	07-01	CF
AbbVie Says Robert Michael Assumes CEO Role	07-01	MT
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer	07-01	PR
AbbVie Announces Board Changes	07-01	CI
AbbVie - Introducing Alle Payment Plans, Powered by Cherry	06-28	AQ
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	PR
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	06-27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
AbbVie: acquisition of Celsius for $250 million	06-27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	06-27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	06-27	MT
AbbVie Acquires Celsius Therapeutics	06-27	PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	AQ

No results for this search